KR20240062623A - Cosmetic compostion comprising phellodendron amurense extract for inhibiting skin glycation - Google Patents
Cosmetic compostion comprising phellodendron amurense extract for inhibiting skin glycation Download PDFInfo
- Publication number
- KR20240062623A KR20240062623A KR1020220144349A KR20220144349A KR20240062623A KR 20240062623 A KR20240062623 A KR 20240062623A KR 1020220144349 A KR1020220144349 A KR 1020220144349A KR 20220144349 A KR20220144349 A KR 20220144349A KR 20240062623 A KR20240062623 A KR 20240062623A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- glycation
- extract
- inhibiting skin
- agents
- Prior art date
Links
- 230000036252 glycation Effects 0.000 title claims abstract description 48
- 239000000284 extract Substances 0.000 title claims abstract description 32
- 230000002401 inhibitory effect Effects 0.000 title claims description 24
- 239000002537 cosmetic Substances 0.000 title claims description 13
- 241000972673 Phellodendron amurense Species 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 57
- 102000008186 Collagen Human genes 0.000 claims abstract description 21
- 108010035532 Collagen Proteins 0.000 claims abstract description 21
- 229920001436 collagen Polymers 0.000 claims abstract description 21
- 108010005094 Advanced Glycation End Products Proteins 0.000 claims abstract description 19
- 230000003834 intracellular effect Effects 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000006071 cream Substances 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 8
- 239000000499 gel Substances 0.000 claims description 8
- 239000006210 lotion Substances 0.000 claims description 7
- 239000002674 ointment Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 241000574138 Ozothamnus diosmifolius Species 0.000 claims description 6
- 240000006079 Schisandra chinensis Species 0.000 claims description 6
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 238000004132 cross linking Methods 0.000 claims description 5
- 210000004292 cytoskeleton Anatomy 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000006260 foam Substances 0.000 claims description 4
- 235000002791 Panax Nutrition 0.000 claims description 3
- 241000208343 Panax Species 0.000 claims description 3
- 241000972672 Phellodendron Species 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- 235000013736 caramel Nutrition 0.000 claims description 3
- 235000019219 chocolate Nutrition 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 235000005911 diet Nutrition 0.000 claims description 3
- 230000037213 diet Effects 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000000865 liniment Substances 0.000 claims description 3
- 229940040145 liniment Drugs 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 235000015927 pasta Nutrition 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 25
- 230000003436 cytoskeletal effect Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 230000009759 skin aging Effects 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 240000004371 Panax ginseng Species 0.000 description 7
- 235000008434 ginseng Nutrition 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 235000002789 Panax ginseng Nutrition 0.000 description 6
- 229940107131 ginseng root Drugs 0.000 description 6
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 6
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 5
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 229940111760 white rice extract Drugs 0.000 description 5
- 206010013911 Dysgeusia Diseases 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 241000209094 Oryza Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 229940015043 glyoxal Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 241000208327 Apocynaceae Species 0.000 description 1
- 241000722818 Aralia Species 0.000 description 1
- 239000005996 Blood meal Substances 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000014824 Crystallins Human genes 0.000 description 1
- 108010064003 Crystallins Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000208326 Gentianales Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000007914 Labor Pain Diseases 0.000 description 1
- 208000035945 Labour pain Diseases 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241001079007 Phellodendron chinense Species 0.000 description 1
- 241000690221 Polypleurum insulare Species 0.000 description 1
- 244000077991 Psidium molle Species 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- UFCGDBKFOKKVAC-DSASHONVSA-N Schisantherin A Chemical compound O([C@H]1C=2C=C(C(=C(OC)C=2C2=C(OC)C=3OCOC=3C=C2C[C@H](C)[C@@]1(O)C)OC)OC)C(=O)C1=CC=CC=C1 UFCGDBKFOKKVAC-DSASHONVSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930186755 gomisin Natural products 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- -1 patches Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 황벽나무 추출물을 포함하여, 콜라겐 당화 억제, 세포골격 당화 억제, 세포 내 RAGEs(최종당화산물 수용체) 생성 억제 및 RAGEs에 의한 염증 억제 효능 중 하나 이상의 효능을 가짐으로써 피부상태 개선 내지 피부 노화 개선 효과를 갖는 조성물을 제공하는 것이다.The present invention includes a Hwangbyulia extract, which has one or more of the following effects: inhibition of collagen glycation, inhibition of cytoskeletal glycation, inhibition of intracellular RAGEs (advanced glycation end product receptor) production, and inhibition of inflammation caused by RAGEs, thereby improving skin condition or skin aging. The object is to provide a composition having an improving effect.
Description
본 발명은 황벽나무 추출물을 포함하는 피부 당화 억제용 조성물, 특히 화장료 조성물에 관한 것이다.The present invention relates to a composition for inhibiting skin glycation, particularly a cosmetic composition, containing an extract of Chrysanthemum chinensis.
당화(glycation)는 당과 단백질 및 지질의 비효소적 반응으로, 환원당의 카르보닐기와 단백질의 유리 아미노기가 반응하여 Schiff base, amadori product 그리고 mailard product를 형성하고, 이렇게 형성된 화합물들은 일련의 반응을 통하여 갈색의 비가역적 최종당화산물(AGEs, Advanced Glycation End products)을 생성한다.Glycation is a non-enzymatic reaction between sugars, proteins, and lipids. The carbonyl groups of reducing sugars react with the free amino groups of proteins to form Schiff base, amadori product, and mailard product. The compounds formed in this way undergo a series of reactions to form a brown color. Generates irreversible advanced glycation end products (AGEs).
인체는 당분 섭취 후 당분을 대사할 때 부담을 느끼게 되는데, 이 때 세포를 손상시키는 활성 산소가 증가하면서 노화를 유발하기 때문이다. 이 과정을 당화라고 하며, 대사기능을 떨어뜨리는 원인 중의 하나이다. The human body feels burdened when metabolizing sugar after consuming it, and this is because free radicals that damage cells increase and cause aging. This process is called glycation, and is one of the causes of decreased metabolic function.
구체적으로, 당화는 표피, 진피 그리고 혈관에 이르기까지 다양한 피부 조직에서 일어나는 현상으로 세포단위에서는 세포 성장을 저해하며, 세포 사멸(apoptosis) 및 세포 휴지(senescence) 단계를 유발하는 것으로 알려져 있다.Specifically, glycation is a phenomenon that occurs in various skin tissues, including the epidermis, dermis, and blood vessels, and is known to inhibit cell growth at the cell level and cause apoptosis and cell senescence.
각질형성세포에서는 NF- κB의 핵 내 유입을 통해 염증매개인자의 발현을 높이며, 활성산소종(ROS)의 생성도 함께 높이는 것으로 보고되고 있다. 섬유아세포에서도 염증매개인자 및 활성산소종의 생성을 높이며, 세포외기질(ECM, Extracellular matrix) 물질인 콜라겐 및 엘라스틴의 발현을 낮추고, 세포외기질분해효소(MMP. Matrix metalloproteinase)의 발현을 높인다. 이로 인해 표피, 진피의 세포 재생 및 항상성이 낮아지며, 콜라겐 및 엘라스틴과 같은 거대섬유의 섬유간 가료(cross-linking)를 유발하여 세포외기질분해효소에 대한 저항성을 갖게 된다. 결국 피부가 뻣뻣해지고 탄력이 감소하며, 세포외기질의 리모델링이 이루어지지 않아 피부 노화가 유도된다.It has been reported that in keratinocytes, the influx of NF-κB into the nucleus increases the expression of inflammatory mediators and also increases the production of reactive oxygen species (ROS). It also increases the production of inflammatory mediators and reactive oxygen species in fibroblasts, lowers the expression of collagen and elastin, which are extracellular matrix (ECM) substances, and increases the expression of matrix metalloproteinase (MMP). This lowers cell regeneration and homeostasis in the epidermis and dermis, and causes cross-linking of large fibers such as collagen and elastin, resulting in resistance to extracellular matrix degrading enzymes. Ultimately, the skin becomes stiff, elasticity decreases, and extracellular matrix remodeling does not occur, leading to skin aging.
일반적인 각질형성세포(28일 주기 세포 사멸)와 달리 long-live cell(Fibroblast, Brain cells, Retina cells 등) 및 long-lasting protein(Collagen, Crystallins, Lens, Cornea 등) 및 DNA에 당화가 진행되면 피부에 심각한 문제를 초래하게 된다. Long-lasting protein인 피부 내 콜라겐의 당화는 인접한 콜라겐섬유와 섬유 사이의 가교(cross-linking)를 매개하여 피부 탄력을 감소시키고 주름을 야기한다. 콜라겐의 당화는 20대부터 시작되어, 매년 3.7%씩 증가하는 것으로 알려져 있으며, 자외선 및 활성산소종 등의 외부 환경에 의해서도 피부 당화 속도가 증가된다고 알려져 있다.Unlike general keratinocytes (28-day cycle of cell death), long-live cells (Fibroblast, Brain cells, Retina cells, etc.), long-lasting proteins (Collagen, Crystallins, Lens, Cornea, etc.) and DNA undergo glycation, causing skin damage. causes serious problems. Glycosylation of collagen in the skin, a long-lasting protein, mediates cross-linking between adjacent collagen fibers, reducing skin elasticity and causing wrinkles. It is known that collagen glycation begins in the 20s and increases by 3.7% every year, and the skin glycation rate is also known to increase due to external environments such as ultraviolet rays and reactive oxygen species.
피부 노화를 억제하기 위한 항산화는 이미 널리 알려져 있으며, 현재 많은 화장품이 존재한다. 최근에는 최종당화산물의 축적이 내인성 노화의 주요 원인으로 주목받고 있으며, 중국 뷰티 시장에서도 항산화가 아닌 항당화를 타겟으로 한 화장품이 주목을 받고 있다. 2022 in-cosmetics korea의 innovation zone에서도 피부 당화를 타겟으로 한 원료들이 전시된 바 있다.Antioxidants to suppress skin aging are already widely known, and many cosmetics currently exist. Recently, the accumulation of advanced glycation end products has been receiving attention as a major cause of endogenous aging, and in the Chinese beauty market, cosmetics that target anti-glycation rather than antioxidants are attracting attention. In the innovation zone of 2022 in-cosmetics Korea, raw materials targeting skin glycation were also exhibited.
하지만, 적절한 효능과 함께 인체 무해한 성분을 포함하는 조성물에 대한 연구가 미흡한 실정이다.However, research on compositions containing ingredients that are harmless to the human body with appropriate efficacy is insufficient.
본 발명은 천연 추출물인 황벽나무 추출물을 포함하는 피부 당화 억제용 조성물을 제공하고자 한다.The present invention seeks to provide a composition for inhibiting skin glycation containing Hwangbyeol chinensis extract, a natural extract.
또한, 상기 조성물을 포함하는 약학적 조성물, 화장료 조성물, 식품 조성물을 제공하고자 한다.In addition, it is intended to provide pharmaceutical compositions, cosmetic compositions, and food compositions containing the above compositions.
본 발명에 따른 피부 당화 억제용 조성물은 황벽나무 추출물을 포함하는 것이 바람직하다.The composition for inhibiting skin glycation according to the present invention preferably contains Hwangbyeol tree extract.
상기 피부 당화 억제용 조성물은 오미자 추출물, 백미꽃 추출물 및 삼칠근 추출물 중 하나 이상을 추가로 포함하는 것이 바람직하다.The composition for inhibiting skin glycation preferably further includes one or more of Schisandra chinensis extract, White rice flower extract, and Panax ginseng root extract.
상기 피부 당화 억제용 조성물은 최종당화산물의 생성을 억제하는 것이 바람직하다.The composition for inhibiting skin glycation preferably suppresses the production of advanced glycation products.
상기 피부 당화 억제용 조성물은 콜라겐 가교를 억제하는 것이 바람직하다.The composition for inhibiting skin glycation preferably inhibits collagen cross-linking.
상기 피부 당화 억제용 조성물은 세포내 세포골격의 당화를 억제하는 것이 바람직하다.The composition for inhibiting skin glycation preferably inhibits glycation of the intracellular cytoskeleton.
상기 피부 당화 억제용 조성물은 최종당화산물 수용체의 발현을 억제하는 것이 바람직하다.The composition for inhibiting skin glycation preferably inhibits the expression of advanced glycation end product receptors.
상기 조성물은 약학적 조성물, 화장료 조성물, 식품 조성물 중 어느 하나인 것이 바람직하다.The composition is preferably one of a pharmaceutical composition, a cosmetic composition, and a food composition.
본 발명에서의 약학 조성물은 정제, 캅셀제, 주사제, 크림, 젤, 팩, 밴드, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 및 카타플라스마제 중 어느 하나의 제형인 것이 바람직하다.The pharmaceutical composition of the present invention may be any one of tablets, capsules, injections, creams, gels, packs, bands, patches, sprays, ointments, warning agents, lotions, liniment agents, pasta agents, and cataplasma agents. desirable.
본 발명에 따른 화장료 조성물은 에어로졸, 액체, 용액, 젤, 페이스트, 팩, 밴드, 패치, 크림, 연고, 폼 및 분말 중 어느 하나의 제형인 것이 바람직하다.The cosmetic composition according to the present invention is preferably in the form of any one of aerosol, liquid, solution, gel, paste, pack, band, patch, cream, ointment, foam, and powder.
본 발명에 따른 식품 조성물은 정제, 캡슐제, 연질캡슐제, 환제, 과립제, 음료, 다이어트바, 쵸콜렛, 카라멜 및 과자류 어느 하나의 제형인 것이 바람직하다.The food composition according to the present invention is preferably in the form of tablets, capsules, soft capsules, pills, granules, beverages, diet bars, chocolate, caramel, and confectionery.
본 발명은 콜라겐 당화 억제, 세포골격 당화 억제, 세포 내 RAGEs(최종당화산물 수용체) 생성 억제 및 RAGEs에 의한 염증 억제 효능 중 하나 이상의 효능을 가짐으로써 피부상태 개선 내지 피부 노화 개선 효과를 갖는 조성물을 제공할 수 있다.The present invention provides a composition that has the effect of improving skin condition or improving skin aging by having one or more of the following effects: inhibition of collagen glycation, inhibition of cytoskeletal glycation, inhibition of intracellular RAGEs (receptor for advanced glycation end products) production, and inhibition of inflammation caused by RAGEs. can do.
도 1은 황벽나무 추출물의 최종당화산물 생성 억제 결과를 개략적으로 도시한 것이다.
도 2는 백미 추출물의 최종당화산물 생성 억제 결과를 개략적으로 도시한 것이다.
도 3은 삼칠근 추출물의 최종당화산물 생성 억제 결과를 개략적으로 도시한 것이다.
도 4는 황벽나무 추출물의 콜라겐 당화 억제 결과를 촬영하여 도시한 것이다.
도 5는 백미 추출물의 콜라겐 당화 억제 결과를 촬영하여 도시한 것이다.
도 6은 삼칠근 추출물의 콜라겐 당화 억제 결과를 촬영하여 도시한 것이다.
도 7은 황벽나무 추출물의 콜라겐 당화 억제 결과를 개략적으로 도시한 것이다.
도 8은 백미 추출물의 콜라겐 당화 억제 결과를 개략적으로 도시한 것이다.
도 9는 삼칠근 추출물의 콜라겐 당화 억제 결과를 개략적으로 도시한 것이다.
도 10은 황벽나무 추출물의 세포 내 세포골격 당화 억제 결과를 촬영하여 개략적으로 도시한 것이다.
도 11은 백미 추출물의 세포 내 세포골격 당화 억제 결과를 촬영하여 개략적으로 도시한 것이다.
도 12는 삼칠근 추출물의 세포 내 세포골격 당화 억제 결과를 촬영하여 개략적으로 도시한 것이다.
도 13은 황벽나무 추출물의 세포 내 최종당화산물 수용체의 발현 억제 결과를 개략적으로 도시한 것이다.
도 14는 백미 추출물의 세포 내 최종당화산물 수용체의 발현 억제 결과를 개략적으로 도시한 것이다.
도 15는 삼칠근 추출물의 세포 내 최종당화산물 수용체의 발현 억제 결과를 개략적으로 도시한 것이다.Figure 1 schematically shows the results of inhibition of advanced glycation end product production by Hwangbyeok tree extract.
Figure 2 schematically shows the results of inhibiting the production of advanced glycation end products in white rice extract.
Figure 3 schematically shows the results of inhibiting the production of advanced glycation end products of the Panax ginseng root extract.
Figure 4 shows the results of inhibition of collagen glycation by Hwangbyeok tree extract.
Figure 5 shows the results of inhibition of collagen glycation by white rice extract.
Figure 6 shows the results of inhibition of collagen glycation by Panax ginseng root extract.
Figure 7 schematically shows the results of inhibition of collagen glycation by Hwangbyeok tree extract.
Figure 8 schematically shows the results of inhibition of collagen glycation by white rice extract.
Figure 9 schematically shows the results of inhibition of collagen glycation by Panax ginseng root extract.
Figure 10 is a schematic illustration of the results of inhibition of intracellular cytoskeletal glycation by Hwangbyeok tree extract.
Figure 11 is a schematic illustration of the results of inhibition of intracellular cytoskeletal glycation by white rice extract.
Figure 12 is a schematic illustration of the results of inhibition of intracellular cytoskeletal glycation by the Panax chinensis root extract.
Figure 13 schematically shows the results of inhibition of expression of intracellular advanced glycation end product receptors by Hwangbyulia extract.
Figure 14 schematically shows the results of inhibition of expression of intracellular advanced glycation end product receptors by white rice extract.
Figure 15 schematically shows the results of inhibiting the expression of intracellular advanced glycation end product receptors in the Panax chinensis root extract.
이하, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 본 발명의 실시형태를 들어 상세히 설명한다. 본 발명의 실시형태는 당업계에서 평균적인 지식을 가진 자에게 본 발명을 더욱 완전하게 설명하기 위해서 제공되는 것이다. 따라서, 본 발명의 실시형태는 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 이하 설명하는 실시형태로 한정되는 것은 아니다.Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily implement it. Embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art. Accordingly, the embodiments of the present invention may be modified into various other forms, and the scope of the present invention is not limited to the embodiments described below.
본 발명의 명세서 전체에서, 어떤 부분이 어떤 구성요소를 “포함”한다고 할 때, 이는 특별히 반대되는 기재가 없는 한 다른 구성요소를 제외하는 것이 아니라 다른 구성요소를 더 포함하는 것을 의미한다.Throughout the specification of the present invention, when a part “includes” a certain component, this means that it does not exclude other components but further includes other components, unless specifically stated to the contrary.
본 발명의 명세서 전체에서, 어떤 단계가 다른 단계와 “상에” 또는 “전에” 위치하고 있다고 할 때, 이는 어떤 단계가 다른 단계와 직접적 시계열적인 관계에 있는 경우뿐만 아니라, 각 단계 후의 혼합하는 단계와 같이 두 단계의 순서에 시계열적 순서가 바뀔 수 있는 간접적 시계열적 관계에 있는 경우와 동일한 권리를 포함할 수 있다.Throughout the specification of the present invention, when a step is said to be located “on” or “before” another step, this means not only when a step is in a direct time-series relationship with another step, but also when a step is in a direct time-series relationship with the other step, as well as a mixing step after each step. Likewise, the order of two steps can include the same rights as in the case of an indirect time-series relationship in which the time-series order can be changed.
본 발명의 명세서 전체에서 사용되는 정도의 용어 “약”, “실질적으로” 등은 언급된 의미에 고유한 제조 및 물질 허용 오차가 제시될 때 그 수치에서 또는 그 수치에 근접한 의미로 사용되고, 본 발명의 이해를 돕기 위해 정확하거나 절대적인 수치가 언급된 개시 내용을 비양심적인 침해자가 부당하게 이용하는 것을 방지하기 위해 사용된다. 본원 명세서 전체에서 사용되는 용어 “~(하는) 단계” 또는 “~의 단계”는 “~를 위한 단계”를 의미하지 않는다.The terms "about", "substantially", etc. used throughout the specification of the present invention are used to mean at or close to that value when manufacturing and material tolerances inherent in the stated meaning are presented, and the present invention Precise or absolute figures are used to aid understanding and to prevent unscrupulous infringers from taking unfair advantage of the disclosure. The term “step of” or “step of” used throughout the specification does not mean “step for.”
본 발명에 따른 피부 당화 억제용 조성물은 황벽나무 추출물을 포함하는 것이 바람직하다.The composition for inhibiting skin glycation according to the present invention preferably contains Hwangbyeol tree extract.
황벽나무는 황백(黃柏). 황벽(黃檗), 황목(黃木)이라고도 한다. 황백은 운향과 (Rutaceae) 황백속 (genus Phellodendron)에 속하는 황벽나무 (Phellodendron amurense Ruprecht) 또는 황피수 (黃皮樹, Phellodendron chinense Schneider)의 줄기껍질로서 주피를 제거한 것이다. <중국약전>의 경우 황피수를 '천황백 (川黃柏)'으로 부르며, 황피수만을 황백의 기원식물로 인정한다. 나무껍질을 약재로 쓴다. 큰황벽나무(Phellodendron amurense var. latifoliolatum NAKAI), 섬황경피나무(P. insulare NAKAI), 우단황벽나무(P. molle NAKAI)의 껍질도 함께 쓰이고 있다. 황벽나무 추출물은 건위, 정장, 수렴, 지사, 해열, 해독, 진통 등의 효능을 가지고 있다. 적용질환은 소화불량, 설사, 복통, 황달, 간염, 간경화증, 소변이 잘 나오지 않는 증세, 자궁출혈 등이다.Hwangbyeok tree is yellow and white. It is also called Hwangbyeok (黃檗) and Hwangmok (黃木). Hwangbaek is the stem bark of Phellodendron amurense Ruprecht or Phellodendron chinense Schneider, which belongs to the genus Phellodendron of the Rutaceae family, with the pericarp removed. In <Chinese Pharmacopoeia>, Hwangpisu is called ‘Cheonhwangbaek (川黃柏)’ and only Hwangpisu is recognized as the origin plant of Hwangbaek. The bark of the tree is used as medicine. The bark of Phellodendron amurense var. latifoliolatum NAKAI, P. insulare NAKAI, and P. molle NAKAI are also used. Hwangbyeok tree extract has health, intestinal, astringent, anti-inflammatory, antipyretic, detoxification, and analgesic effects. Applicable diseases include indigestion, diarrhea, abdominal pain, jaundice, hepatitis, liver cirrhosis, difficulty urinating, and uterine bleeding.
상기 피부 당화 억제용 조성물은 오미자 추출물, 백미꽃 추출물 및 삼칠근 추출물 중 하나 이상을 추가로 포함하는 것이 바람직하다.The composition for inhibiting skin glycation preferably further includes one or more of Schisandra chinensis extract, White rice flower extract, and Panax ginseng root extract.
백미꽃은 용담목(Gentianales) 박주가리과(Asclepiadaceae)에 속하는 다년생 초본식물로, 뿌리가 하얗고 가늘어 백미라는 이름이 붙었다. White rice flower is a perennial herbaceous plant belonging to the Asclepiadaceae family of Gentianales. It is named white rice because of its white and thin roots.
백미꽃은 가을이나 이른 봄에 뿌리를 캐서 햇볕에 잘 말린 뒤 물에 달여 약용하는데, 백미꽃의 뿌리를 말린 것을 한방에서는 백미라 한다. 열이 높거나 손발이 부을 때 효능이 있는 것으로 알려져 있다. 뿌리는 해열작용이 있어 폐결핵으로 조열이 있는 데나 혈열·허열에 약재로 쓰인다. 또 폐결핵으로 인한 토혈·신장염·요로감염증과 열성병 말기의 작열감 등을 해소시키는 효능이 있다. 전신부종과 임질에도 효과가 있다. 한국·일본·중국·몽골 등에 분포하는 것으로 알려져 있다.The roots of white rice flowers are dug up in the fall or early spring, dried well in the sun, and then decocted in water for medicinal purposes. In Oriental medicine, the dried roots of white rice flowers are called white rice. It is known to be effective when fever is high or hands and feet are swollen. The root has an antipyretic effect, so it is used as a medicine for fever due to pulmonary tuberculosis, blood fever, and ischemic fever. It is also effective in relieving vomiting of blood due to pulmonary tuberculosis, nephritis, urinary tract infection, and burning sensation in the final stage of febrile illness. It is also effective for systemic edema and gonorrhea. It is known to be distributed in Korea, Japan, China, and Mongolia.
오미자는 오미자나무의 열매로 지름 약 1cm의 짙은 붉은 빛깔이다. 단맛·신맛·쓴맛·짠맛·매운맛을 느낄 수 있어 오미자라고 불린다. 시잔드린·고미신·시트럴·사과산·시트르산 등의 성분이 들어 있어 심장을 강하게 하고 혈압을 내리며 면역력을 높여 주어 강장제로 쓴다. 폐 기능을 강하게 하고 진해·거담 작용이 있어서 기침이나 갈증 등을 치료하는 데 도움이 된다.Schisandra chinensis is the fruit of the Schisandra chinensis tree and is about 1cm in diameter and dark red in color. It is called Schisandra chinensis because it can taste sweet, sour, bitter, salty, and spicy. It contains ingredients such as cizandrine, gomisin, citral, malic acid, and citric acid, and is used as a tonic as it strengthens the heart, lowers blood pressure, and increases immunity. It strengthens lung function and has antitussive and expectorant properties, so it helps treat cough and thirst.
삼칠근은 우리나라에서는 두릅나무과의 삼칠(Panax notoginsengs(Burk) F. H. Chen:三七)의 뿌리를 말한다. 중국에서는 우리나라와 같고 일본에서는 공정생약으로 수재되지 않았다. 삼칠은 혈분에 들어 지혈작용을 하므로 어혈을 없애주어 각종 출혈 증상, 즉 토혈, 코피, 객혈, 대소변출혈 등에 쓰며 타박골절상, 어혈로 인한 복통, 종기, 진통, 산후에 피를 많이 흘리는 증상에 사용한다. 약리작용은 혈액응고시간 단축, 항피로효과, 혈압강하, 심장박동이완, 관상동맥혈류량 증가, 지질용해작용, 간기능증진, 면역기능활성화 등이 보고되었다.In Korea, Samchi root refers to the root of Panax notoginsengs (Burk) F. H. Chen: 三七 of the Aralia family. In China, it is the same as in Korea, and in Japan, it has not been approved as a processed herbal medicine. As ginseng is contained in blood meal and has a hemostatic effect, it eliminates stagnation of blood and is used for various bleeding symptoms such as hematemesis, nosebleeds, hemoptysis, bleeding in the bowels and urine, etc. It is also used for contusion fractures, abdominal pain due to stagnation, boils, labor pains, and symptoms of excessive bleeding after childbirth. . Pharmacological effects have been reported to include shortening of blood coagulation time, anti-fatigue effect, lowering of blood pressure, relaxation of heart rate, increase in coronary blood flow, lipid dissolution, improvement of liver function, and activation of immune function.
상기 피부 당화 억제용 조성물은 최종당화산물의 생성을 억제하는 것이 바람직하다.The composition for inhibiting skin glycation preferably suppresses the production of advanced glycation products.
상기 피부 당화 억제용 조성물은 콜라겐 가교를 억제하는 것이 바람직하다.The composition for inhibiting skin glycation preferably inhibits collagen cross-linking.
상기 피부 당화 억제용 조성물은 세포내 세포골격의 당화를 억제하는 것이 바람직하다.The composition for inhibiting skin glycation preferably inhibits glycation of the intracellular cytoskeleton.
상기 피부 당화 억제용 조성물은 최종당화산물 수용체의 발현을 억제하는 것이 바람직하다.The composition for inhibiting skin glycation preferably inhibits the expression of advanced glycation end product receptors.
상기 조성물은 약학적 조성물, 화장료 조성물, 식품 조성물 중 어느 하나인 것이 바람직하다.The composition is preferably one of a pharmaceutical composition, a cosmetic composition, and a food composition.
본 발명에서의 약학 조성물은 정제, 캅셀제, 주사제, 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 및 카타플라스마제 등을 포함하는 군에서 선택되는 제형일 수 있으나 이에 제한되지는 않는다.The pharmaceutical composition in the present invention may be a dosage form selected from the group including tablets, capsules, injections, creams, gels, patches, sprays, ointments, warning agents, lotions, liniment agents, pasta agents, cataplasma agents, etc. However, it is not limited to this.
본 발명의 약학적 조성물은 제제시에 통상적으로 사용되는 약제학적으로 허용되는 담체, 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다.The pharmaceutical composition of the present invention may further include pharmaceutically acceptable carriers, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc. commonly used in preparation.
본 발명의 약학적 조성물은 경구 또는 비경구 투여할 수 있으며, 비경구 투여인 경우에는 정맥내 주입, 피하 주입, 근육 주입, 복강 주입, 경피 투여, 점막 투여 및 점안 투여, 국소투여 등의 방식으로 투여할 수 있으나, 이에 제한되는 것은 아니다.The pharmaceutical composition of the present invention can be administered orally or parenterally, and in case of parenteral administration, it can be administered through methods such as intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, mucosal administration, eye drop administration, and local administration. It can be administered, but is not limited to this.
본 발명의 약학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 섭취 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있다. 바람직하게는, 본 발명의 약학적 조성물의 투여량은 성인 기준으로 0.0001-100 ㎎/kg(체중)일 수 있으나 이에 제한되는 것은 아니다.The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, ingested food, administration time, administration route, excretion rate, and reaction sensitivity. may be prescribed. Preferably, the dosage of the pharmaceutical composition of the present invention may be 0.0001-100 mg/kg (body weight) for adults, but is not limited thereto.
본 발명에 추가될 수 있는 적합한 성분의 선택은, 당업자에게 자명한 범위에서, 본 발명의 피부 외용제 조성물이 용액, 로션, 림, 연고, 겔, 폼 또는 경피 패치로 제형화 되는지 여부에 어느 정도 의존할 것이다.The selection of suitable ingredients that can be added to the present invention, as will be apparent to those skilled in the art, depends to some extent on whether the external skin composition of the present invention is formulated as a solution, lotion, cream, ointment, gel, foam, or transdermal patch. something to do.
예를 들어, 착색제(색소), 착향제(향료), 현탁화제, 유화제, 용해보조제, 안정제, 등장제, pH조절제, 점도조절제, 용제 등을 포함할 수 있다. 화장료 조성물에 통상적으로 부가되는 성분이나 함량 등은 당업자에게 자명할 것이다.For example, it may include colorants (pigments), flavoring agents (flavors), suspending agents, emulsifiers, solubilizing agents, stabilizers, isotonic agents, pH adjusters, viscosity adjusters, solvents, etc. The ingredients and contents commonly added to cosmetic compositions will be apparent to those skilled in the art.
본 발명에 따른 화장료 조성물은 에어로졸, 액체, 용액, 젤, 페이스트, 크림, 연고, 폼 및 분말 중 어느 하나의 제형으로 가능하며, 이에 제한되지 않는다.The cosmetic composition according to the present invention can be in any one of the following formulations: aerosol, liquid, solution, gel, paste, cream, ointment, foam, and powder, but is not limited thereto.
예를 들어, 로션은 용액과 유사하지만 용액보다 더 진하고 본질적으로 더 완화시키는 경향이 있다. 로션에는 일반적으로 물과 오일이 혼합되어 있으며 용액보다 알코올이 적은 경우가 많다.For example, lotions are similar to solutions, but tend to be thicker and more emollient in nature. Lotions are usually a mixture of water and oil and often contain less alcohol than a solution.
예를 들어, 크림은 거의 같은 비율의 오일과 물의 에멀젼을 가지고 있다. 피부의 각질층 외층까지 잘 침투한다. 크림은 로션보다 두껍고 용기에서 꺼낼 때 모양이 유지된다.For example, creams are an emulsion of approximately equal proportions of oil and water. It penetrates well into the outer layer of the skin's stratum corneum. Creams are thicker than lotions and retain their shape when removed from the container.
또한, 본 발명의 조성물은 팩, 밴드 또는 패치 중 어느 하나에 포함될 수 있으며, 이에 제한되지 않는다.Additionally, the composition of the present invention may be included in any one of a pack, band, or patch, but is not limited thereto.
상기 팩은 국소형 패치, 시트타입, 거즈타입, 크림타입 및 젤타입 중 어느 하나의 형태일 수 있다.The pack may be in the form of any one of topical patch, sheet type, gauze type, cream type, and gel type.
상기 팩은 마스크팩, 손팩, 발팩, 종아리팩, 헤어팩, 허벅지팩, 복부팩, 옆구리팩, 팔뚝팩, 턱팩 및 목팩 중에서 선택되는 어느 하나일 수 있다.The pack may be any one selected from a mask pack, hand pack, foot pack, calf pack, hair pack, thigh pack, abdominal pack, side pack, forearm pack, chin pack, and neck pack.
한편, 식품 조성물에 적용할 경우에는 본 발명에 따른 조성물을 유효성분으로 하여 당 분야에서 통상적으로 사용되는 성분들을 적의 선정하여, 정제, 캡슐제, 연질캡슐제, 환제, 과립제, 음료(드링크제), 다이어트바, 쵸콜렛, 카라멜 제형 또는 과자류 제형 등으로 제형화하여 사용할 수 있다. 또한 건강식품에 적합한 기능성원료를 부가적으로 적절하게 사용할 수 있다.On the other hand, when applied to a food composition, the composition according to the present invention is used as an active ingredient and ingredients commonly used in the art are appropriately selected to produce tablets, capsules, soft capsules, pills, granules, beverages (drinks), It can be formulated into diet bars, chocolate, caramel formulations, or confectionery formulations. Additionally, functional raw materials suitable for health foods can be additionally and appropriately used.
이하에서는 본 발명에 따른 황벽나무 추출물을 포함하는 조성물의 구체적인 실시예 및 실험예를 통해 본 발명을 보다 구체적으로 설명한다.Hereinafter, the present invention will be described in more detail through specific examples and experimental examples of a composition containing the Hwangbyeol tree extract according to the present invention.
(실시예 1) 황벽나무 추출물 제조(Example 1) Preparation of Hwangbyeok tree extract
건조된 황벽나무를 분쇄하여 분말 50 g에 70% 에탄올 1 L을 넣고 실온에서 3시간 동안 500 rpm으로 교반하면서 추출하였다. 여과지를 이용하여 추출 용액을 여과하여 회수한 뒤, 감압 농축기를 이용해 60℃에서 감압 농축을 진행하였으며, 용매를 완전히 제거함으로써 분말형태의 황벽나무 70% 에탄올 추출물을 수득하였다.The dried Hwangbyeok tree was pulverized, 1 L of 70% ethanol was added to 50 g of powder, and extracted while stirring at 500 rpm for 3 hours at room temperature. After filtering and recovering the extraction solution using filter paper, it was concentrated under reduced pressure at 60°C using a vacuum concentrator, and the solvent was completely removed to obtain a 70% ethanol extract of Phellodendron chinensis in powder form.
(실시예 2~3) 백미 및 삼칠근 추출물 제조(Examples 2-3) Preparation of white rice and Panax ginseng extract
건조된 백미 및 삼칠근을 분쇄하여 상기 실시예 1과 동일한 방법에 따라 각각의 추출물을 수득하였다.Dried white rice and ginseng root were pulverized to obtain respective extracts in the same manner as in Example 1 above.
(실험예 1) 최종당화산물 생성 억제 평가(Experimental Example 1) Evaluation of inhibition of advanced glycation end product formation
0.1M 인산완충액(Phosphate buffer) (PBS, pH7.4, contained 0.02% sodium azide)에 0.5M의 글루코스(glucose)와 10㎎/㎖의 BSA(Bovine Serum Albumin)를 넣고, 37℃에서 반응시켰다. 실시예 1~3을 넣고, 21일간 비효소적 반응을 유도한 뒤, 355~460nm 파장에서 형광도를 측정하여 최종당화산물(AGEs)의 생성 억제 정도를 확인하였다. 양성대조군은 아미노구아니딘(aminoguanidine)을 사용하였다.0.5 M glucose and 10 mg/ml BSA (Bovine Serum Albumin) were added to 0.1 M phosphate buffer (PBS, pH 7.4, containing 0.02% sodium azide), and reacted at 37°C. Examples 1 to 3 were added, a non-enzymatic reaction was induced for 21 days, and fluorescence was measured at a wavelength of 355 to 460 nm to confirm the degree of inhibition of advanced glycation end products (AGEs). Aminoguanidine was used as a positive control group.
실험 결과, 실시예 1에 의해 BSA의 당화가 억제됨을 확인하였다(도 1~3 참조).As a result of the experiment, it was confirmed that glycation of BSA was inhibited by Example 1 (see FIGS. 1 to 3).
(실험예 2) 콜라겐 당화 억제 평가(Experimental Example 2) Evaluation of collagen glycation inhibition
인간 유래 섬유아세포를 플레이트에서 24시간 배양한 뒤, 400μM의 글리옥살(glyoxal) 및 실시예 1을 처리하여 5일간 배양하였다. 트립신(Trypsin)을 이용하여 세포를 회수하고, FBS(Fetal bovine serum)로 다시 현탁한 뒤, 콜라겐 혼합물에 넣고 혼합하였다. Anti-Link™(Allvivo Vascular 社)가 처리된 24-well 플레이트에서 1시간 배양한 후, 10% FBS가 포함된 배지를 상층부에 넣어주었다. 24시간 배양한 후, 콜라겐의 가교(cross-linking)된 양을 확인하였다.Human-derived fibroblasts were cultured on a plate for 24 hours, then treated with 400 μM glyoxal and Example 1 and cultured for 5 days. Cells were recovered using trypsin, resuspended in FBS (fetal bovine serum), and then added to the collagen mixture and mixed. After culturing for 1 hour in a 24-well plate treated with Anti-Link™ (Allvivo Vascular), medium containing 10% FBS was added to the upper layer. After culturing for 24 hours, the amount of cross-linked collagen was confirmed.
실험 결과, 실시예 1~3에 의해 콜라겐의 결합이 억제됨을 확인하였다(도 4~9 참조).As a result of the experiment, it was confirmed that collagen binding was inhibited by Examples 1 to 3 (see Figures 4 to 9).
(실험예 3) 세포 내 세포골격 당화 억제 평가(Experimental Example 3) Evaluation of inhibition of intracellular cytoskeletal glycosylation
인간 유래 섬유아세포를 플레이트에서 24시간 배양한 뒤, 400μM의 글리옥살 및 실시예 1~3을 처리하여 5일간 배양하였다. 트립신을 이용하여 세포를 회수하고, 8 mm 커버글래스에서 24시간 동안 배양하였다. 배지를 제거하고, 3.7% 포름알데히드(formaldehyde)를 이용해 세포를 고정한 뒤, 0.1% triton X-100을 처리하였다. Anti-vimentin antibody를 넣어 반응시키고, 2차 항체(antibody)를 붙인 뒤, confocal laser scanning microscopy를 이용하여 cytoskeletal fiber의 분포를 확인하였다.Human-derived fibroblasts were cultured on a plate for 24 hours, then treated with 400 μM glyoxal and Examples 1 to 3 and cultured for 5 days. Cells were recovered using trypsin and cultured on 8 mm cover glass for 24 hours. The medium was removed, the cells were fixed using 3.7% formaldehyde, and then treated with 0.1% triton X-100. Anti-vimentin antibody was added and reacted, a secondary antibody was attached, and the distribution of cytoskeletal fibers was confirmed using confocal laser scanning microscopy.
실험 결과, 당화가 유도된 세포 골격은 핵 주변에 뭉쳐 있는 것을 확인할 수 있었고, 실시예 1~3에 의해 세포 골격이 뻗어 나감으로써 당화가 억제됨을 확인하였다(도 10~12 참조).As a result of the experiment, it was confirmed that the glycosylation-induced cytoskeleton was clustered around the nucleus, and in Examples 1 to 3, it was confirmed that glycosylation was inhibited by the cytoskeleton extending (see FIGS. 10 to 12).
(실험예 4) 세포 내 최종당화산물 수용체 발현 억제 평가(Experimental Example 4) Evaluation of inhibition of intracellular advanced glycation end product receptor expression
인간 유래 섬유아세포를 플레이트에서 24시간 동안 배양한 뒤, 400μM의 글리옥살 및 실시예 1~3을 처리하여 5일간 배양하였다. 배양액을 제거하고, RIPA lysis buffer를 이용하여 세포를 용해시킨 후, 원심분리하여 단백질을 획득하였다. BCA 단백질 정량을 통해 동량의 단백질 샘플을 확보한 후, SDS-PAGE를 통해 단백질을 크기에 따라 분리하였다. Electrotransfer로 세포 단백질을 PVDF 멤브레인에 옮기고 immunoblot을 통하여 최종당화산물 수용체(RAGE, Receptor for advanced glycation end products)의 발현 수준을 확인하였다.Human-derived fibroblasts were cultured on a plate for 24 hours, then treated with 400 μM glyoxal and Examples 1 to 3 and cultured for 5 days. The culture medium was removed, cells were lysed using RIPA lysis buffer, and proteins were obtained by centrifugation. After securing an equal amount of protein sample through BCA protein quantification, proteins were separated according to size through SDS-PAGE. Cell proteins were transferred to the PVDF membrane by electrotransfer, and the expression level of receptor for advanced glycation end products (RAGE) was confirmed through immunoblot.
실험 결과, 실시예 1에 의해 최종당화산물 수용체의 발현이 억제됨을 확인하였다(도 13~15 참조).As a result of the experiment, it was confirmed that the expression of the advanced glycation end product receptor was suppressed by Example 1 (see FIGS. 13 to 15).
이상에서 본 발명의 실시예에 대하여 상세하게 설명하였지만 본 발명의 권리범위는 이에 한정되는 것은 아니고, 청구범위에 기재된 본 발명의 기술적 사상을 벗어나지 않는 범위 내에서 다양한 수정 및 변형이 가능하다는 것은 당 기술분야의 통상의 지식을 가진 자에게는 자명할 것이다.Although the embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and variations are possible without departing from the technical spirit of the present invention as set forth in the claims. This will be self-evident to those with ordinary knowledge in the field.
Claims (10)
The composition according to claim 7, wherein the food composition is included in any one of tablets, capsules, soft capsules, pills, granules, beverages, diet bars, chocolate, caramels, and confectionery.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220144349A KR102681194B1 (en) | 2022-11-02 | 2022-11-02 | Cosmetic compostion comprising phellodendron amurense extract for inhibiting skin glycation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220144349A KR102681194B1 (en) | 2022-11-02 | 2022-11-02 | Cosmetic compostion comprising phellodendron amurense extract for inhibiting skin glycation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20240062623A true KR20240062623A (en) | 2024-05-09 |
| KR102681194B1 KR102681194B1 (en) | 2024-07-03 |
Family
ID=91075638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220144349A KR102681194B1 (en) | 2022-11-02 | 2022-11-02 | Cosmetic compostion comprising phellodendron amurense extract for inhibiting skin glycation |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102681194B1 (en) |
Citations (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020000400A (en) | 2000-06-24 | 2002-01-05 | 서경배 | A composition for skin external application having effects of suppressing glycation intermediates and advanced glycation endproducts(AGEs) formation |
| KR20050073917A (en) * | 2004-01-12 | 2005-07-18 | 주식회사 생그린 | Cosmetic composition comprising plant extract having anti-aging effect |
| KR20140118960A (en) * | 2014-08-28 | 2014-10-08 | 주식회사 코스메카코리아 | A Cosmetic Composition for Whitening Skin Containing Cynanchum atratum Extracts |
| KR20150002048A (en) * | 2013-06-28 | 2015-01-07 | 주식회사 코스메카코리아 | A composition for preventing wrinkle of skin and anti aging of skin |
| KR20150045420A (en) | 2015-04-13 | 2015-04-28 | 바이오스펙트럼 주식회사 | Composition for blocking AGEs production comprising Akebia quinata extracts |
| KR20170136912A (en) * | 2016-06-02 | 2017-12-12 | 주식회사 엘지생활건강 | Composition for improving skin condition comprising herb extracts mixture |
| KR20170136930A (en) * | 2016-06-02 | 2017-12-12 | 주식회사 엘지생활건강 | Composition for improving skin condition comprising herb extracts mixture |
| KR20170136918A (en) * | 2016-06-02 | 2017-12-12 | 주식회사 엘지생활건강 | Composition for improving skin condition comprising herb extracts mixture |
| KR20170137548A (en) * | 2016-06-03 | 2017-12-13 | 주식회사 엘지생활건강 | Composition for improving skin condition comprising herb extracts mixture |
| KR20170137539A (en) * | 2016-06-03 | 2017-12-13 | 주식회사 엘지생활건강 | Composition for improving skin condition comprising herb extracts mixture |
| KR101958454B1 (en) | 2017-09-08 | 2019-03-18 | 바이오스펙트럼 주식회사 | Composition for blocking AGEs production and promoting AGEs decomposition comprising defatted Torreya nucifera's seed extract |
| KR102014903B1 (en) * | 2017-08-17 | 2019-08-28 | 바이오스펙트럼 주식회사 | Composition for blocking AGEs production and promoting AGEs decomposition comprising Korthalsella japonica extracts |
| KR20190137328A (en) | 2018-06-01 | 2019-12-11 | 애경산업(주) | Skin external application composition for anti-aging containing Rhodotypos scandens extract |
| KR20200049007A (en) * | 2018-10-31 | 2020-05-08 | 주식회사 리앤투네이쳐 | Cosmetic composition for preventing skin aging |
| KR20200049187A (en) * | 2018-10-31 | 2020-05-08 | 인하대학교 산학협력단 | Composition for skin anti-aging comprising extract of silverwave melon(Cucumis melo) |
| KR20200068126A (en) * | 2018-12-04 | 2020-06-15 | 한국식품연구원 | Composition comprising a extract of Schizonepeta tenuifolia having Advanced Glycation End product inhibitory activity effects |
| KR20210025316A (en) * | 2019-08-27 | 2021-03-09 | 코스맥스 주식회사 | Composition for improving skin beauty comprising extract of fermented roots of Panax notoginseng by Aspergillus cristatus strain |
| JP2022157675A (en) * | 2021-03-31 | 2022-10-14 | ポーラ化成工業株式会社 | Cell death inhibitor and gata6-as1 expression promoter, as well as method of use thereof and screening method thereof |
| KR102491017B1 (en) * | 2021-09-28 | 2023-01-20 | 주식회사 에스앤비랩 | Composition for Anti-glycation, Anti-oxidation, Anti-Wrinkle, and Moisturizing Property Comprising Seaweed and Peptide as Active Ingredient |
-
2022
- 2022-11-02 KR KR1020220144349A patent/KR102681194B1/en active IP Right Grant
Patent Citations (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020000400A (en) | 2000-06-24 | 2002-01-05 | 서경배 | A composition for skin external application having effects of suppressing glycation intermediates and advanced glycation endproducts(AGEs) formation |
| KR20050073917A (en) * | 2004-01-12 | 2005-07-18 | 주식회사 생그린 | Cosmetic composition comprising plant extract having anti-aging effect |
| KR20150002048A (en) * | 2013-06-28 | 2015-01-07 | 주식회사 코스메카코리아 | A composition for preventing wrinkle of skin and anti aging of skin |
| KR20140118960A (en) * | 2014-08-28 | 2014-10-08 | 주식회사 코스메카코리아 | A Cosmetic Composition for Whitening Skin Containing Cynanchum atratum Extracts |
| KR20150045420A (en) | 2015-04-13 | 2015-04-28 | 바이오스펙트럼 주식회사 | Composition for blocking AGEs production comprising Akebia quinata extracts |
| KR20170136912A (en) * | 2016-06-02 | 2017-12-12 | 주식회사 엘지생활건강 | Composition for improving skin condition comprising herb extracts mixture |
| KR20170136930A (en) * | 2016-06-02 | 2017-12-12 | 주식회사 엘지생활건강 | Composition for improving skin condition comprising herb extracts mixture |
| KR20170136918A (en) * | 2016-06-02 | 2017-12-12 | 주식회사 엘지생활건강 | Composition for improving skin condition comprising herb extracts mixture |
| KR20170137548A (en) * | 2016-06-03 | 2017-12-13 | 주식회사 엘지생활건강 | Composition for improving skin condition comprising herb extracts mixture |
| KR20170137539A (en) * | 2016-06-03 | 2017-12-13 | 주식회사 엘지생활건강 | Composition for improving skin condition comprising herb extracts mixture |
| KR102014903B1 (en) * | 2017-08-17 | 2019-08-28 | 바이오스펙트럼 주식회사 | Composition for blocking AGEs production and promoting AGEs decomposition comprising Korthalsella japonica extracts |
| KR101958454B1 (en) | 2017-09-08 | 2019-03-18 | 바이오스펙트럼 주식회사 | Composition for blocking AGEs production and promoting AGEs decomposition comprising defatted Torreya nucifera's seed extract |
| KR20190137328A (en) | 2018-06-01 | 2019-12-11 | 애경산업(주) | Skin external application composition for anti-aging containing Rhodotypos scandens extract |
| KR20200049007A (en) * | 2018-10-31 | 2020-05-08 | 주식회사 리앤투네이쳐 | Cosmetic composition for preventing skin aging |
| KR20200049187A (en) * | 2018-10-31 | 2020-05-08 | 인하대학교 산학협력단 | Composition for skin anti-aging comprising extract of silverwave melon(Cucumis melo) |
| KR20200068126A (en) * | 2018-12-04 | 2020-06-15 | 한국식품연구원 | Composition comprising a extract of Schizonepeta tenuifolia having Advanced Glycation End product inhibitory activity effects |
| KR20210025316A (en) * | 2019-08-27 | 2021-03-09 | 코스맥스 주식회사 | Composition for improving skin beauty comprising extract of fermented roots of Panax notoginseng by Aspergillus cristatus strain |
| JP2022157675A (en) * | 2021-03-31 | 2022-10-14 | ポーラ化成工業株式会社 | Cell death inhibitor and gata6-as1 expression promoter, as well as method of use thereof and screening method thereof |
| KR102491017B1 (en) * | 2021-09-28 | 2023-01-20 | 주식회사 에스앤비랩 | Composition for Anti-glycation, Anti-oxidation, Anti-Wrinkle, and Moisturizing Property Comprising Seaweed and Peptide as Active Ingredient |
Non-Patent Citations (1)
| Title |
|---|
| 황백 열수추출물의 피부노화 억제 효과 및 화장품 소재 활용에 관한 연구, 계명대학교 대학원 학위논문, 배인순(2009.) 1부.* * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102681194B1 (en) | 2024-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kumar et al. | Systematic pharmacognostical, phytochemical and pharmacological review on an ethno medicinal plant, Basella alba L | |
| KR102533052B1 (en) | Korean traditional herbs shampoo composition | |
| US10098372B2 (en) | Whitening composition and the use thereof | |
| CN103893345B (en) | Composition containing a natural extract | |
| KR20200106577A (en) | Composition for anti-oxidant, anti-inflammatory and relieving swelling containing plant complex extracts | |
| US10434057B2 (en) | Cosmetic composition comprising osmanthus asiaticus extract and clematis apiifolia extract | |
| KR102030275B1 (en) | Hair cleanser composition | |
| JP2016160198A (en) | Kaempferia parviflora-containing compositions | |
| CN116509939A (en) | A composition for inhibiting skin glycation | |
| KR101820531B1 (en) | Composition for preventing hair loss or promoting hair growth with Nipa fruticans wurmb | |
| US20240115642A1 (en) | Composition for preventing hair loss or promoting hair growth comprising milk thistle flower extract as an active ingredient | |
| KR102681194B1 (en) | Cosmetic compostion comprising phellodendron amurense extract for inhibiting skin glycation | |
| JP2019147824A (en) | Kaempferia parviflora-containing compositions | |
| KR102258283B1 (en) | Inflammation or allergy treatment and improvement composition comprising a natural product fermentation complex extract as an active ingredient and a method of manufacturing the same | |
| KR20150002048A (en) | A composition for preventing wrinkle of skin and anti aging of skin | |
| KR20170137405A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR20220082974A (en) | A composition for stimulating growth of hairs contaning rhynchosia nulubilis complex extracts | |
| KR20200048305A (en) | Pharmaceutical composition for preventing or treating vitiligo comprising extract of Ricinus communis as an active ingredient | |
| KR20150061124A (en) | Cosmetic composition comprising fermented plant as effective component | |
| KR101747499B1 (en) | Composition for preventing skin aging, treating wrinkled skin, preventing and treating dermatitis comprising lindera sericea extract | |
| KR101682458B1 (en) | Cosmetic composition for slimming | |
| KR102250928B1 (en) | Cosmetic composition containing Trapa japonica Flerov callus extracts | |
| CN116549527A (en) | A composition for inhibiting skin glycation | |
| KR20130032995A (en) | Anti inflammatory composition comprising tamarindus indica extract as effective composition | |
| KR20150140620A (en) | A cosmetic composition comprising Zizyphus jujuba extract for slimming |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right |